The gene-editing treatment will be available to certain patients with sickle cell disease in England as Vertex commits to collecting additional data.

The UK’s Medicines and Healthcare Regulatory Agency (MHRA) approved Casgevy for sickle cell disease in 2023, followed by ...

The gene therapy Casgevy, which will now be offered to some patients in England, could help people live disease-free, experts ...

The UK has approximately 17,500 individuals living with sickle cell disease, a condition particularly prevalent amongst those ...

One of the world’s most expensive medicines will be used to treat some patients with sickle cell disease in England using the state-funded National Health Service.Most Read from BloombergHow the 2025 ...

The growing use of AI has opened new avenues for healthcare marketers, revolutionising how they approach new initiatives.

However, significant barriers stand in the way of realising this promise on a worldwide scale, from manufacturing costs and ...

Columnist Mary Shaniqua, who undergoes monthly transfusions because of sickle cell, thanks the blood donors who make it ...

Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

CHOP doctors Thompson and Grupp have devoted their lives to improving the quality and length of life for children with sickle ...

What’s more, some analysts suggest there is a ready-made buyer in CRISPR’s partner on Casgevy, Vertex Pharmaceuticals. Now Vertex is a massive company with a market cap of $106bn and more than ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across several programs- -Starting 2025 with a strong balance sheet with ...